Literature DB >> 19364450

Drug-induced parkinsonism.

Frandy Susatia1, Hubert H Fernandez.   

Abstract

Drug-induced parkinsonism (DIP) is condition that mimics Parkinson's disease. Characterized mainly by rigidity and bradykinesia, it has less prominent tremor and gait instability. DIP is generally caused by lipophilic drugs that "block" dopamine D2 receptors in the brain, although presynaptic dopamine depletion, false transmitters, mitochondrial respiratory chain dysfunction, and overactivity in the gamma-aminobutyric acid (GABA)ergic system or cholinomimetic action have also been postulated as possible mechanisms. The onset of DIP is acute to subacute. It is more common in women and has a bimodal age distribution. Other diseases that can resemble DIP include neuropsychiatric conditions (eg, depression, negative symptoms of schizophrenia) and Wilson's disease. Physicians may be able to prevent DIP by prescribing neuroleptic agents appropriately and with caution. The risk of DIP is presumably lower with the use of "atypical" antipsychotic agents but it is not eliminated, especially in those most vulnerable to parkinsonism (eg, the elderly or cognitively impaired). The best treatment is discontinuation of the provoking medication. Prospective studies are needed to further define the mechanism of DIP, identify individual susceptibility, determine the impact of atypical antipsychotic agents, and develop further treatment options for those unable to stop the offending agent.

Entities:  

Year:  2009        PMID: 19364450     DOI: 10.1007/s11940-009-0019-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  58 in total

1.  Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.

Authors:  Shitij Kapur; Robert A McClelland; Susan C VanderSpek; Marie-Louise G Wadenberg; Glen Baker; Jose Nobrega; Robert B Zipursky; Philip Seeman
Journal:  Neuroreport       Date:  2002-05-07       Impact factor: 1.837

2.  Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.

Authors:  A L Nordström; L Farde; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Understanding drug-induced parkinsonism: separating pearls from oy-sters.

Authors:  Maria Victoria G Alvarez; Virgilio Gerald H Evidente
Journal:  Neurology       Date:  2008-02-19       Impact factor: 9.910

Review 4.  Review: drug-induced parkinsonism in elderly patients.

Authors:  J A Wilson; W J MacLennan
Journal:  Age Ageing       Date:  1989-05       Impact factor: 10.668

5.  Toxic effects of amantadine in patients with renal failure.

Authors:  T S Ing; J T Daugirdas; L S Soung; H L Klawans; S D Mahurkar; J A Hayashi; W P Geis; J E Hano
Journal:  Can Med Assoc J       Date:  1979-03-17       Impact factor: 8.262

Review 6.  Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis.

Authors:  D Tarsy
Journal:  Clin Neuropharmacol       Date:  1983       Impact factor: 1.592

7.  Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study.

Authors:  L Ganzini; R Heintz; W F Hoffman; G A Keepers; D E Casey
Journal:  J Geriatr Psychiatry Neurol       Date:  1991 Oct-Dec       Impact factor: 2.680

Review 8.  Drug-induced parkinsonism: a review.

Authors:  J L Montastruc; M E Llau; O Rascol; J M Senard
Journal:  Fundam Clin Pharmacol       Date:  1994       Impact factor: 2.748

9.  Clinical characteristics of neuroleptic-induced parkinsonism.

Authors:  S Hassin-Baer; P Sirota; A D Korczyn; T A Treves; B Epstein; H Shabtai; T Martin; Y Litvinjuk; N Giladi
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

10.  Drug-induced parkinsonism.

Authors:  J A Van Gerpen
Journal:  Neurologist       Date:  2002-11       Impact factor: 1.398

View more
  16 in total

1.  Inducible ablation of dopamine D2 receptors in adult mice impairs locomotion, motor skill learning and leads to severe parkinsonism.

Authors:  E P Bello; R Casas-Cordero; G L Galiñanes; E Casey; M A Belluscio; V Rodríguez; D Noaín; M G Murer; M Rubinstein
Journal:  Mol Psychiatry       Date:  2016-07-19       Impact factor: 15.992

2.  Extrapyramidal examinations in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2012-07

3.  Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs.

Authors:  Ingo Vogt; Jeanette Prinz; Mónica Campillos
Journal:  Genome Med       Date:  2014-08-17       Impact factor: 11.117

4.  Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage.

Authors:  Jeremy D Fields; Justin S Cetas
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

5.  The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism.

Authors:  Tommaso Bovi; Angelo Antonini; Sarah Ottaviani; Angela Antonioli; Maria Paola Cecchini; Vincenzo Di Francesco; Maria Antonietta Bassetto; Mauro Zamboni; Antonio Fiaschi; Giuseppe Moretto; Andrea Sbarbati; Francesco Osculati; Michele Tinazzi
Journal:  J Neurol       Date:  2010-07-16       Impact factor: 4.849

6.  Parkinsonism caused by adverse drug reactions: a case series.

Authors:  Solomon O Ugoya; Emmanuel I Agaba; Comfort A Daniyam
Journal:  J Med Case Rep       Date:  2011-03-16

7.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

Review 8.  Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

Authors:  Lior Greenbaum; Bernard Lerer
Journal:  Front Neurol       Date:  2015-02-20       Impact factor: 4.003

9.  Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

Authors:  Lydia E Pieters; P Roberto Bakker; Peter N van Harten
Journal:  Front Psychiatry       Date:  2018-02-05       Impact factor: 4.157

10.  Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine.

Authors:  Kai-Ming Jhang; Jing-Yang Huang; Oswald Ndi Nfor; Yu-Chun Tung; Wen-Yuan Ku; Chun-Te Lee; Yung-Po Liaw
Journal:  Eur J Clin Pharmacol       Date:  2017-04-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.